| 韩 娜,朱建光,田彦卿,刘凡平,王 辉,张晨钰,李占英.氨溴索注射液治疗COPD合并肺结核患者的疗效及对血清IL-6、TNF-α水平的影响[J].现代生物医学进展英文版,2019,19(7):1317-1320. |
| 氨溴索注射液治疗COPD合并肺结核患者的疗效及对血清IL-6、TNF-α水平的影响 |
| Clinical Efficacy of Ambroxol Injection in the Treatment of COPD Complicated with Pulmonary Tuberculosis and Its Impact on the Serum Serum IL-6 and TNF-α Levels |
| Received:June 28, 2018 Revised:July 22, 2018 |
| DOI：10.13241/j.cnki.pmb.2019.07.026 |
| 中文关键词: 氨溴索注射液 慢性阻塞性肺疾病 肺结核 白介素-6 肿瘤坏死因子-α |
| 英文关键词: Ambroxol Injection COPD PTB IL-6 TNF-α |
| 基金项目:河北省中医药管理局科研项目（20162083） |
| Author Name | Affiliation | E-mail | | HAN Na | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | hanna_198103@163.com | | ZHU Jian-guang | Department of Otolaryngology, PLA 252 Hospital, Baoding, Hebei, 071000, China | | | TIAN Yan-qing | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | | | LIU Fan-ping | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | | | WANG Hui | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | | | ZHANG Chen-yu | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | | | LI Zhan-ying | Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China | |
|
| Hits: 900 |
| Download times: 725 |
| 中文摘要: |
| 摘要 目的：观察氨溴索注射液治疗慢性阻塞性肺疾病(COPD)合并肺结核(PTB)患者的临床疗效及对患者血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平的影响。方法：选取2015年1月~2018年1月我院诊治的COPD合并PTB患者181例，按照入院先后顺序分为对照组和观察组。对照组90例，给予常规对症药物治疗。观察组91例，在对症治疗的基础上加用氨溴索注射液。两组均持续治疗8周。比较两组临床有效率、病灶吸收和空洞闭合有效率、临床症状积分、肺功能及治疗前后血清IL-6和TNF-α水平的变化。结果：治疗后，观察组和对照组的总有效率分别为95.60%、74.44%，观察组显著高于对照组，两组相比具有统计学差异(P＜0.05)；观察组治疗后病灶吸收有效率和症状积分均明显优于对照组(P＜0.05)，空洞闭合有效率与对照组相比差异无统计学意义(P＞0.05)；观察组治疗后用力呼气量(FVC)、一秒用力呼气容积(FEV1)和FEV1/FVC值显著高于对照组(P＜0.05)，血清IL-6和TNF-α水平均显著低于对照组(P＜0.05)。结论：氨溴索注射液可显著提高COPD合并PTB患者的临床疗效，改善临床症状、病灶吸收和空洞闭合有效率和肺功能，可能与其有效降低血清IL-6和TNF-α水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of ambroxol injection in the treatment of COPD combined with PTB and its impact on the serum IL-6 and TNF-α levels. Methods: 181 cases of patients with COPD and PTB treated in the Affiliated Hospital of Hebei University were selected from January 2015 to January 2018 and divided into the control group and the observation group accord- ing to the order of admission. In the control group, 90 cases were treated with conventional symptomatic drugs. In the observation group, 91 cases were treated with ambroxol injection on the basis of symptomatic treatment. Both groups were treated for 8 weeks. The clinical efficacy, nidus absorption status, void closure status, symptom scores, lung function and changes of serum IL-6, TNF-α levels before and after treatment were compared between two groups. Results: After treatment, the total effective rate of observation group and control group were 95.60% and 74.44% respectively, which was significantly higher in the observation group than that of the control group(P<0.05); the nidus absorption status and symptomatic score of observation group were better than those of the control group(P<0.05), there was no significant difference in the void closure status between two groups(P＞0.05). The values of FVC, FVC and FEV1/FVC of obser- vation group were significantly higher than those in the control group(P<0.05), the serum levels of IL-6 and TNF-α in the observation group were significantly lower than those in the control group(P<0.05). Conclusion: Ambroxol injection can significantly improve the clinical symptoms, nidus absorption status, void closure status and lung function in the treatment of COPD combined with PTB, it may be related to the effective reduction of serum IL-6 and TNF-α levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
